Print page
Email page
Download PDF
« Previous Release | Next Release »
REDWOOD CITY, Calif., Jan 5, 2010 (GlobeNewswire via COMTEX News Network) -- Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's chief executive officer, will present at the J.P. Morgan 28th Annual Healthcare Conference on Thursday, January 14, at 1:00 p.m. Pacific Time. The conference will take place at the Westin St. Francis in San Francisco. Dr. Selick will provide an overview of Threshold and its clinical development program for TH-302, a novel drug candidate for the potential treatment of solid tumors.
A live webcast of the presentation will be available under the Webcasts section of the Company's website. A replay of the presentation will be archived on the site for 90 days.
About Threshold Pharmaceuticals
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website (www.thresholdpharm.com).
This news release was distributed by GlobeNewswire, www.globenewswire.com
SOURCE: Threshold Pharmaceuticals, Inc.
CONTACT: Threshold Pharmaceuticals, Inc. Denise T. Powell, Sr. Director, Corporate Communications 650-474-8206 dpowell@thresholdpharm.com
(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.
News Provided by COMTEX